Search Result

Results for "

AMPA receptor antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Calcium Channel (6) Carbonic Anhydrase (6) Cytochrome P450 (2) GABA Receptor (6) iGluR (52) Isotope-Labeled Compounds (1) LPL Receptor (1) Potassium Channel (6) Sodium Channel (6)
By Research Areas:	Cancer (2) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (48)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-129030

BDZ-g	iGluR	Neurological Disease
BDZ-g is a potent, selective antagonist of *AMPA* receptor. BDZ-g has the potential for the research of various neurological disorders involving excessive activity of AMPA receptors .

HY-12506A

Naspm trihydrochloride 5+ Cited Publications 1-Naphthylacetyl spermine trihydrochloride	iGluR	Neurological Disease
Naspm trihydrochloride (1-Naphthylacetyl spermine trihydrochloride), a synthetic analogue of Joro spider toxin, is a calcium permeable AMPA (CP-AMPA) receptors antagonist.

HY-12506

Naspm 5+ Cited Publications 1-Naphthylacetyl spermine	iGluR	Neurological Disease
Naspm (1-Naphthyl acetyl spermine), a synthetic analogue of Joro spider toxin, is a calcium permeable AMPA (CP-AMPA) receptors antagonist.

HY-15068

NBQX Maximum Cited Publications 10 Publications Verification FG9202	iGluR	Neurological Disease
NBQX (FG9202) is a highly selective and competitive **AMPA receptor** antagonist. NBQX has neuroprotective and anticonvulsant activity .

HY-136905

AMPA receptor antagonist-2	iGluR	Others
AMPA receptor antagonist-2 (example 23) is an **AMPA receptor** antagonist .

HY-145959

AMPA receptor antagonist-3	iGluR	Neurological Disease
AMPA receptor antagonist-3 is an **AMPA receptor** antagonist extracted from patent US20070027143A1. AMPA receptor antagonist-3 can be used for the research of central nervous system disorders .

HY-124539

ZK 187638	iGluR	Neurological Disease
ZK 187638 is an **AMPA receptor** antagonist. ZK 187638 antagonizes the kainate-induced currents in cultured hippocampal neurons with an IC₅₀ of 3.4 μM in a noncompetitive fashion .

HY-15070

YM 900	iGluR	Neurological Disease
YM 900 is an **AMPA receptor** antagonist .

HY-100815

(R)-AMPA	iGluR	Neurological Disease
(R)-AMPA is an inactive AMPA receptor ligand that inhibits the release of excitatory amino acids from neurons. (R)-AMPA is inactive in experiments that enhance the release of [3H]D-aspartate induced by electrical stimulation. (R)-AMPA is inhibited by competitive and noncompetitive AMPA receptor selective antagonists in response to AMPA and glutamate .

HY-107603

NS3763	iGluR	Neurological Disease
NS3763 is a selective and noncompetitive GLU_K5 receptor antagonist with an IC₅₀ of 1.6 µM. NS3763 does not show significant antagonistic properties on GLU_K6, AMPA or NMDA receptors .

HY-19433A

(S)-ATPO	iGluR	Neurological Disease
(S)-ATPO is the (S)-enantiomer of ATPO, which is a competitive antagonist at GluR1-4 (AMPA-preferring) receptors .

HY-108707

LY3130481 1 Publications Verification	iGluR	Neurological Disease
LY3130481 is an orally available *AMPA* receptor antagonist, selectively inhibiting the IC₅₀ value of AMPA/TARP γ-8 at 65 nM. LY3130481 has anticonvulsant, antiepileptic, and pain-relieving effects .

HY-106039

LY 215490	iGluR	Neurological Disease
LY 215490 is a selective, competitive **AMPA receptor** antagonist against *AMPA, CGSl9755* and kainate with IC₅₀ values of 4.8, 26.4 and 247 μM, respectively. LY 215490 shows neuroprotective effects in focal ischaemia .

HY-15068A

NBQX disodium Maximum Cited Publications 10 Publications Verification FG9202 disodium	iGluR	Neurological Disease
NBQX disodium (FG9202 disodium) is a highly selective and competitive **AMPA receptor** antagonist. NBQX disodium has neuroprotective and anticonvulsant activity .

HY-18663B

CP-465022 hydrochloride	iGluR	Neurological Disease
CP-465022 hydrochloride is a potent, and selective noncompetitive **AMPA receptor** antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC₅₀ of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .

HY-18663A

CP-465022 maleate	iGluR	Neurological Disease
CP-465022 Maleate is a potent, and selective noncompetitive **AMPA receptor** antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC₅₀ of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .

HY-18663

CP-465022	iGluR	Neurological Disease
CP-465022 is a potent, and selective noncompetitive **AMPA receptor** antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC₅₀ of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .

HY-118814

YM928	iGluR	Neurological Disease
YM928 is an orally active and noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist. YM928 inhibits **AMPA receptor**-mediated toxicity in primary rat hippocampal cultures with an IC₅₀ value of 2 μM. YM928 blocks AMPA-induced intracellular calcium influx with an IC₅₀ value of 3 μM and antagonizes AMPA-induced inward currents with an IC₅₀ value of 1 μM. YM928 is promising for research of neurological disorders .

HY-15072

Zonampanel YM 872	iGluR	Metabolic Disease
Zonampanel (YM 872) is a selective antagonist of the glutamate receptor subtype, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor.

HY-15066

CNQX Maximum Cited Publications 10 Publications Verification FG9065	iGluR	Neurological Disease
CNQX (FG9065) is a potent and competitive **AMPA/kainate receptor** antagonist with IC₅₀s of 0.3 μM and 1.5 μM, respectively. CNQX is a competitive non-NMDA receptor antagonist . CNQX blocks the expression of fear-potentiated startle in rats .

HY-15067

DNQX 5 Publications Verification FG 9041	iGluR	Cancer
DNQX (FG 9041), a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC₅₀s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively) .

HY-103233

DNQX disodium salt FG 9041 disodium salt	iGluR	Cancer
DNQX (FG 9041) disodium salt, a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC₅₀s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively) .

HY-107606

UBP301	iGluR	Neurological Disease
UBP301 is a potent and selective antagonist of kainate receptor with IC₅₀ and K_D of 164 μM and 5.94 μM, respectively. UBP301 has ∼30-fold selectivity of kainate receptor over AMPA receptor. UBP301 is the derivative of willardiine .

HY-107606A

UBP301 hydrochloride	iGluR	Neurological Disease
UBP301 hydrochloride is a potent and selective antagonist of kainate receptor with IC₅₀ and K_D of 164 μM and 5.94 μM, respectively. UBP301 hydrochloride has ～30-fold selectivity of kainate receptor over AMPA receptor. UBP301 hydrochloride is the derivative of willardiine .

HY-15066A

CNQX disodium Maximum Cited Publications 10 Publications Verification FG9065 disodium	iGluR	Neurological Disease
CNQX disodium (FG9065 disodium) is a potent and competitive **AMPA/kainate receptor** antagonist with IC₅₀s of 0.3 μM and 1.5 μM, respectively. CNQX disodium is a competitive non-NMDA receptor antagonist . CNQX disodium blocks the expression of fear-potentiated startle in rats .

HY-15071

YM90K	iGluR	Neurological Disease
YM90K is a potent and selective **AMPA receptor** antagonist with a K_i of 84 nM. YM90K is less potent in inhibiting kainate (K_i of 2.2 μM) and NMDA (K_i of 37 μM) receptors. YM90K has neuroprotective actions .

HY-117176

KRP-199	iGluR	Neurological Disease
KRP-199 (compound 14h) is an α-amino-3-hydroxy-5-methylisoxazolepropionic acid receptor (AMPA-R) antagonist (K_i=16 nM) with high potency and selectivity for *AMPA-R* in vitro and good neuroprotective effects in vivo. KRP-199 can be used in the study of neurodegenerative diseases .

HY-18689

SYM2206	iGluR	Neurological Disease
SYM2206 is a potent and non-competitive **AMPA receptor** antagonist, with an IC₅₀ of 1.6 μM. SYM2206 blocks Na_v1.6-mediated persistent currents .

HY-105860

Selurampanel BGG 492	iGluR	Neurological Disease
Selurampanel (BGG 492) is an orally active and competitive **AMPA receptor** antagonist with an IC₅₀ of 190 nM. Selurampanel has reasonable blood-brain barrier penetration. Selurampanel can be used for epilepsy research .

HY-100785A

gamma-DGG acetate γDGG acetate; γ-D-Glutamylglycine acetate	iGluR	Neurological Disease
gamma-DGG acetate (γDGG acetate) is a competitive **AMPA receptor blocker. gamma-DGG acetate is also a reversible Excitatory post-synaptic potentials** (e.p.s.p.s) antagonist .

HY-107518

(R,S)-3,4-Dicarboxyphenylglycine (R,S)-3,4-DCPG	iGluR	Neurological Disease
(R,S)-3,4-Dicarboxyphenylglycine ((RS)-3,4-DCPG) is an *AMPA* receptor antagonist. (R,S)-3,4-Dicarboxyphenylglycine antagonizes AMPA-mediated depolarization of motor neurons in neonatal rats. (R,S)-3,4-Dicarboxyphenylglycine can be used in the study of neurological diseases .

HY-107605

UBP296	iGluR	Neurological Disease
UBP296 is a potent and selective antagonist of GLU_K5-containing kainate receptor in the spinal cord. UBP296 reversibly blocks ATPA-induced depressions of synaptic transmission, and affects AMPA receptor-mediated synaptic transmission directly in rat hippocampal slices .

HY-121964

cis-Piperidine-2,3-dicarboxylic acid	iGluR	Neurological Disease
Cis-piperidine-2,3-dicarboxylic acid is a non-specific antagonist of NMDA, AMPA and kainate ionotropic receptors and a partial agonist for NMDA receptors. Cis-piperidine-2,3-dicarboxylic acid can be used in blocking general excitatory synaptic transmissions .

HY-106467B

Caroverine hydrochloride	iGluR	Neurological Disease
Caroverine hydrochloride is a potent, competitive and reversible antagonist of NMDA and **AMPA glutamate receptor. Caroverine hydrochloride is also an antioxidant and calcium-blocking** agent that exhibits vasorelaxant action. Caroverine hydrochloride can be used for the research of inner ear tinnitus .

HY-106467

Caroverine	iGluR	Neurological Disease
Caroverine is a potent, competitive and reversible antagonist of NMDA and **AMPA glutamate receptor. Caroverine is also an antioxidant and calcium-blocking** agent that exhibits vasorelaxant action. Caroverine can be used for the research of inner ear tinnitus .

HY-114379

AS2717638 1 Publications Verification	LPL Receptor	Inflammation/Immunology
AS2717638 is an oral active and selective *lysophosphatidic acid receptor* 5 (LPA5)** antagonist, with an IC₅₀ of 38 nM for hLPA5. AS2717638 also significantly improves PGE₂-, PGF_2α-, and AMPA-induced allodynia .

HY-15078

NS1219 (R)-SPD502	iGluR	Neurological Disease
NS1219 ((R)-SPD502) is the isomer of NS 1209 HY-15074. NS1209 is a selective **AMPA receptor** antagonist with neuroprotective activity. NS1209 can be used for the research of stroke, neuropathic pain and epilepsy .

HY-B0122

Topiramate 4 Publications Verification McN 4853; RWJ 17021	iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase	Neurological Disease
Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of *kainate/AMPA* receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-B0122A

Topiramate lithium McN 4853 lithium; RWJ 17021 lithium	iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase	Neurological Disease
Topiramate (McN 4853) lithium is a broad-spectrum antiepileptic agent. Topiramate lithium is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of *kainate/AMPA* receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-15074

SPD-502 NS-1209	iGluR	Neurological Disease
SPD-502 is a novel glutamate antagonist with potential neuroprotective properties, particularly in brain ischemia. It selectively targets the AMPA receptor, showing high affinity (IC₅₀ = 0.043 μM) and competitive inhibition of AMPA-induced effects in rat cortical membranes and cultured mouse cortical neurons. In vivo, SPD-502 effectively blocks AMPA-evoked spike activity in the hippocampus after intravenous administration, significantly increasing the seizure threshold in mice and demonstrating robust protection against ischemia-induced damage to hippocampal neurons in gerbils. These findings suggest SPD-502 may be promising for treating neurodegenerative conditions associated with glutamate excitotoxicity .

HY-15076

SPD-502 sodium NS-1209 sodium	iGluR	Neurological Disease
SPD-502 sodium is a novel glutamate antagonist with potential neuroprotective properties, particularly in brain ischemia. It selectively targets the AMPA receptor, showing high affinity (IC₅₀ = 0.043 μM) and competitive inhibition of AMPA-induced effects in rat cortical membranes and cultured mouse cortical neurons. In vivo, SPD-502 sodium effectively blocks AMPA-evoked spike activity in the hippocampus after intravenous administration, significantly increasing the seizure threshold in mice and demonstrating robust protection against ischemia-induced damage to hippocampal neurons in gerbils. These findings suggest SPD-502 sodium may be promising for treating neurodegenerative conditions associated with glutamate excitotoxicity .

HY-19435A

GYKI-47261 dihydrochloride	iGluR Cytochrome P450	Neurological Disease
GYKI-47261 dihydrochloride is a competitive, orally active, and selective **AMPA receptor** antagonist with an IC₅₀ of 2.5 μM. GYKI-47261 has broad spectrum anticonvulsive activity and neuroprotective effects. GYKI-47261 dihydrochloride is also a potent inducer of CYP2E1 .

HY-19435

GYKI-47261	iGluR Cytochrome P450	Neurological Disease
GYKI-47261 is a competitive, orally active, and selective **AMPA receptor** antagonist with an IC₅₀ of 2.5 μM. GYKI-47261 has broad spectrum anticonvulsive activity and neuroprotective effects. GYKI-47261 is also a potent inducer of CYP2E1 .

HY-124160

JNJ-56022486	iGluR	Neurological Disease
JNJ-56022486 is an orally active and potent negative **AMPA receptor** modulator (K_i=19 nM) selective for?TARP-γ8. JNJ-56022486 is also a TARP-γ8 receptor antagonist, with blood?brain?barrier (BBB) permeability. JNJ-56022486 can be used for research of Epilepsy .

HY-103234A

GYKI 52466 dihydrochloride	iGluR	Neurological Disease
GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive **AMPA/kainate receptor** antagonist with the IC₅₀ values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research .

HY-103234

GYKI 52466	iGluR	Neurological Disease
GYKI 52466 is an orally active, highly selective and noncompetitive **AMPA/kainate receptor** antagonist with the IC₅₀ values of 7.5 and 11μM, respectively. GYKI 52466 has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 can be used in Parkinson's disease research .

HY-103234B

GYKI 52466 hydrochloride	iGluR	Neurological Disease
GYKI 52466 hydrochloride is an orally active, highly selective and noncompetitive **AMPA/kainate receptor** antagonist with the IC₅₀ values of 7.5 and 11μM, respectively. GYKI 52466 hydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 hydrochloride can be used in Parkinson's disease research .

HY-110234

Topiramate D12 McN 4853 D12 ; RWJ 17021 D12	iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase	Neurological Disease
Topiramate D12 (McN 4853 D12) is a deuterium labeled Topiramate. Topiramate is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of *kainate/AMPA* receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-B0122R

Topiramate (Standard)	iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase	Neurological Disease
Topiramate (Standard) is the analytical standard of Topiramate. This product is intended for research and analytical applications. Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-19432

UBP-282	iGluR	Neurological Disease
UBP-282 is a potent, selective and competitive *AMPA* and kainate receptor antagonist. UBP-282 inhibits the fast component of the dorsal root-evoked ventral root potential (fDR-VRP) with an IC₅₀ value of 10.3 μM. UBP-282 antagonizes kainate-induced depolarisations of dorsal roots with a pA₂ value of 4.96 .

Cat. No.	Product Name	Chemical Structure

HY-B0122S

Topiramate-13C6

Topiramate-13C6 (McN 4853-13C6) is the ¹³C labeled isotope of Topiramate (HY-B0122). Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: